ライフサイエンスコーパス: ORR

1 ORR in PD-L1-positive patients was 60% (n = 9) v 19% (n

2 ORR in the intention-to-treat (ITT) population was 17% (

3 ORR increased with higher TMB, plateauing at 10 or more

4 ORR was 28.6% (95% CI, 24.1% to 33.5%); 33 patients (8.9

5 ORR was 30% overall and 41% and 15% in patients with 1%

6 ORR was 30.6% (95% CI, 20.0% to 47.5%) for all patients

7 ORR was 32% for the first 25 enrolled patients (8 PR [7

8 ORR was 36% (15 of 42 patients).

9 ORR was 37.5% with a complete response rate of 12.5%, me

10 ORR was 42% with nivolumab and 14% with dacarbazine; amo

11 ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus

12 ORR(W15) for the entire population was 42%; it was signi

13 ORR(week24) was as follows: RCC, 63% (19/30; 95% CI, 43.

14 ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 3

15 ORRs were similar for patients with a germline or somati

16 sented improved efficacy in PFS (P = 0.033), ORR (P < 0.001), and DCR (P < 0.001).

17 In cohort 1, ORR was 33% (90% CI, 19% to 51%) and in cohort 2, 31% (9

18 In patients with CPS >= 10, ORR was 47.3% (95% CI, 37.7% to 57.0%) and median OS was

19 cohort's objective response rate at week 15 (ORR(W15)).

20 en only with gPALB2 (ORR, 82%) and sBRCA1/2 (ORR, 50%) mutations.

21 tive was objective response rate at week 24 (ORR(week 24)) at the recommended phase II dose.

22 the high selectivity and activity for 2e(-) ORR.

23 ygen-functionalized carbon can promote 2e(-) ORR in acidic electrolytes.

24 A wide range tuning of 2e(-)/4e(-) ORR pathways was achieved via different metal centers or

25 ponse rate (ORR); the null hypothesis (<= 5% ORR) would be rejected within each cohort if there were

26 vel platinum-group-metals-free highly active ORR electrocatalysts in alkaline media.

27 The 3 most active ORR electrocatalysts were MnCo(2)O(4)/C, CoMn(2)O(4)/C,

28 ) nanoparticles with an exceptional activity-ORR and OER current densities of 7.21 and 6.85 mA cm(-2)

29 In addition, ORR on Mn-N-C and Co-N-C SACs is unveiled.

30 % (95% CI, 70.0-97.8) with BID dosing and an ORR of 79.2% (95% CI, 57.9-92.9) and an estimated PFS ra

31 48 patients were to be accrued to detect an ORR of 42%.

32 ier-positive DLBCL patients (de novo) had an ORR of 44%, median progression-free survival (mPFS) of 6

33 n unusually complete mechanistic study of an ORR reaction.

34 urvival (mPFS) of 6 months, and 16% CR vs an ORR of 19%, mPFS of 1.5 months, and 5% CR in classifier-

35 his study met its primary end point, with an ORR of 38% (P < .0001) in this mixed histology, pretreat

36 ian of three prior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%).

37 and pembrolizumab with chemotherapy, with an ORR, DCR and median duration of response of 32%, 77% and

38 he ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were withi

39 ction of some fundamentals of fuel cells and ORR catalysts with performance metrics is provided, foll

40 omplete remission rate per investigator, and ORR of 70% (51% to 85%), with a 43% complete metabolic r

41 ntify the kinetics of the HER, HOR, OER, and ORR in acidic and basic solutions are provided, and exam

42 ers reduced complete remission (CR) rate and ORR with VenG.

43 f cobalt nitrides (Co(x)N/C, x = 2, 3, 4) as ORR electrocatalysts in alkaline fuel cells.

44 tic tests, we identified the cobalt nodes as ORR active sites.

45 challenges and future directions of Pt-based ORR catalysts for fuel cells are also presented.

46 roving the catalytic performance of Pt-based ORR catalysts, including the development of various Pt n

47 Best ORR at any time was 73.2% (complete response, 56.3%).

48 The best ORR achieved was 68% (30 of 44).

49 The best ORR catalyst in the alloy NP series we studied is L1(0)-

50 Secondary end points were best ORR during the first 6 months, overall survival, progres

51 Secondary objectives were best ORR, overall survival (OS), progression-free survival (P

52 eline SMD and clinical outcomes, nor between ORR, irAEs and baseline SMI (data not shown).

53 Nitrate removal by ORR isolate Pseudomonas fluorescens N2A2 is virtually ab

54 or the mechanism of iron porphyrin-catalyzed ORR and provides an unusually complete mechanistic study

55 of responses were observed in the cisplatin (ORR 23%) and doxorubicin (ORR 35%) cohorts.

56 In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohor

57 The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of

58 ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%).

59 The confirmed ORR was 38% (90% CI, 22.9% to 54.9%) with P < .0001 agai

60 Confirmed ORRs per independent radiology review and investigator a

61 high Fe(III/II) potential with a correlated ORR onset potential within 150 mV of Fe-N-C.

62 been applied to understanding and designing ORR catalysts, it has also been recognized that these un

63 In patients with lymph node-only disease, ORR was 49.0% (95% CI, 34.8% to 63.4%), and median OS wa

64 inib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or deat

65 in the cisplatin (ORR 23%) and doxorubicin (ORR 35%) cohorts.

66 vation affirms that FePc demetalation during ORR proceeds via a direct loss of Fe(2+) and that carbon

67 on relation of Pt-alloy nanocatalysts during ORR demands concerted efforts in precision synthesis, ad

68 egradation to FePc have been observed during ORR.

69 neous iridium porphyrins for high-efficiency ORR catalysis.

70 [Fe(2)(SH)](+) is an efficient ORR catalyst both in the presence of a one-electron redu

71 To produce efficient ORR catalysts with low Pt content, PtNi porous films (PF

72 anotubes exhibits excellent electrocatalytic ORR activity (E(1/2) =0.83 V vs. RHE, n=3.93, and j(L) =

73 2)O(2)/H(2)O selectivity in electrocatalytic ORR by iron(tetramesitylporphyrin) (Fe(TMP)) in DMF.

74 duce 90-100 % H(2) O(2) from electrochemical ORR catalysis in neutral pH water, whereas the Co-TPP mo

75 roton exchange membrane (PEM) electrolyzers, ORR-related PEM fuel cells, NRR-driven ammonia electrosy

76 lays excellent selectivity for four-electron ORR, comparable to Fe-N-C materials.

77 lectrocatalytic activity toward two-electron ORR to H(2)O(2), a future green "dream" process for chem

78 al volcano trends for four- and two-electron ORR.

79 olcano accounting for favorable two-electron ORR.

80 erimental ORR was compared with an estimated ORR of 60% based on historical data, verified by a rando

81 al and mechanistic basis for the exceptional ORR activity of M-N-C electrocatalysts impedes rational

82 PGM-free Fe-N-C electrocatalysts now exhibit ORR activities approaching that of PGM electrocatalysts

83 The experimental ORR was compared with an estimated ORR of 60% based on h

84 Regardless of PD-L1 expression, ORRs were higher in patients with TMB of 10 or more mut/

85 nce-Tafel slopes of 35 and 38 mV dec(-1) for ORR and OER, respectively-resulting in the lowest ORR ov

86 bits promising electrocatalytic activity for ORR with a half-wave potential of 0.89 V in 0.1 M NaOH,

87 PD-L1+ and PD-L1- patients, was assessed for ORR, disease control rate, and safety, but not survival.

88 astuzumab) and -15% to 15% with a 95% CI for ORR difference.

89 undaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to

90 ials' high-efficiency as electrocatalyst for ORR.

91 arbon-based, metal-free electrocatalysts for ORR and various defects in metal oxides/selenides for OE

92 lations, we present a microkinetic model for ORR on Fe-N-C SACs, disclosing a self-adjusting mechanis

93 lectrochemical, and catalytic properties for ORR to a typical Fe-N-C material and prototypical pyrrol

94 he electrocatalytic activity/selectivity for ORR (H(2)O(2) and H(2)O products) and H(2)O(2) reduction

95 mplate, by a facile host-guest strategy, for ORR in alkaline media.

96 sitive versus PRESSING-negative subgroup for ORR (59.2% v 75.3%; P = .030), PFS (7.7 v 12.1 months; P

97 erved in right- versus left-sided tumors for ORR (55.2% v 74.1%; P = .037), PFS (8.4 v 11.5 months; P

98 n this area has been carbon-based metal-free ORR electrocatalysts.

99 uture development of carbon-based metal-free ORR electrocatalysts.

100 g the main causes of instability of PGM-free ORR catalysts in acidic environments, focusing on transi

101 freedom for each marker effect obtained from ORR and use it to deshrink both the estimated effect and

102 firmed responses were seen only with gPALB2 (ORR, 82%) and sBRCA1/2 (ORR, 50%) mutations.

103 y end points were similar in the two groups: ORR 16% (complete response [CR]/partial responses[PRs],

104 of the five above-mentioned reactions (HER, ORR, CO(2) RR, NRR, and OER), the current challenges fac

105 g H(2)O(2) productivity considering its high ORR activity, highest H(2)O(2) selectivity, and lowest H

106 the surface gives rise to the observed high ORR and OER electrocatalytic activity and small discharg

107 The N-C-CoO(x) catalyst showed high ORR activity, indicated by excellent half-wave (0.84 V v

108 trocatalysts exhibit an unprecedentedly high ORR activity with a half-wave potential (E(1/2) ) of 0.9

109 num-based nanocrystals that enable very high ORR activities in acidic media; however, improving the a

110 .74; 95% CI, 0.67 to 0.82; P < .001), higher ORR (64.5% v 53.6%; P < .001), higher R0 resection rate

111 ients with high BCL2 expression had a higher ORR (94% [17/18]) than patients with low BCL2 expression

112 d Ir-SAC exhibits orders of magnitude higher ORR activity than iridium nanoparticles with a record-hi

113 Co(4)N/C exhibited the highest ORR activity among the three types of cobalt nitrides st

114 diiron complex that can act as a homogeneous ORR catalyst in acetonitrile solution.

115 However, ORR has never been used for GWAS due to its severe shrin

116 Although there was no difference in ORR, the association with clinically relevant reduced to

117 Fe/Al-contaminated acidic environments like ORR or acid mine drainage sites has the potential to imp

118 ng unsolvated (in case of PF(6) (-)) lowered ORR activation barriers with a 200-mV lower overpotentia

119 nd OER, respectively-resulting in the lowest ORR overpotential of 4.0 mV and OER overpotential of 5.1

120 The primary end point was 6-month ORR assessed with independent central review by using mo

121 The 6-month ORR was 52% (23 of 44).

122 At a median follow-up of 11.1 months, ORR (95% CI) was 73% (54% to 88%), with a 37% complete r

123 rasmall and ordered L1(0) -PtCo nanoparticle ORR catalysts further doped with a few percent of metals

124 l current applied after 20 000 s for the OER/ORR/HER reactions.

125 first section, we start with the activity of ORR on the nanoscale surface and then focus on the appro

126 Analysis of ORR sediments revealed recalcitrant Mo in the contaminat

127 Density functional theory calculations of ORR and OER on Mo(3) P (110) reveal that an oxide overla

128 enables the rapid and reliable evaluation of ORR activity using standard rotating disk electrode (RDE

129 ion process can be correlated with a loss of ORR activity suggesting that Fe-containing sites are ess

130 The various multi-step pathways of ORR are firstly reviewed and the rate-determining steps

131 vity toward H(2)O(2) and a positive shift of ORR onset potential by ~320 mV compared with the OCNT su

132 the standard error so that the Wald test of ORR is brought back to the same level as that of EMMA.

133 ect evaluation of the effect of the order on ORR catalytic activity.

134 sults indicate that the achieved outstanding ORR performance results from the synergetic enhancement

135 h-SA electrocatalyst exhibits an outstanding ORR activity, outperforming SA electrocatalysts with onl

136 s paves a new avenue toward high-performance ORR electrocatalysts.

137 + bevacizumab and provides advantage in PFS, ORR, and R0 resection rate at the price of a moderate in

138 Closely related cobalt porphyrin ORR catalysts can function closer to the O(2)/H(2)O ther

139 diates are more crucial for cobalt porphyrin ORR catalysts.

140 portant in the performance of iron porphyrin ORR catalysts, we suggest that electrostatic stabilizers

141 that have been developed for iron porphyrin ORR electrocatalysts to improve the performance of the c

142 .5 %) Ni PF) was obtained, showing prominent ORR activity with an onset potential of 0.92 V (vs.

143 imary end point was objective response rate (ORR) according to RECIST (version 1.1).

144 Objective response rate (ORR) and progression-free survival (PFS) were calculated

145 come of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria.

146 imary end point was objective response rate (ORR) at 24 weeks (ORR(Wk24)); secondary efficacy end poi

147 primary end point was overall response rate (ORR) at day 28; the key secondary end point was duration

148 primary end point was overall response rate (ORR) by RECIST version 1.1.

149 point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the fi

150 Although the overall response rate (ORR) for GClb was lower in patients with del(17p), del(1

151 The objective response rate (ORR) for single-agent anti-programmed death receptor 1 (

152 imary end point was objective response rate (ORR) in patients with 1% or more and less than 1% tumor

153 rametinib led to an objective response rate (ORR) of 78%, including 44% complete responses (CRs).

154 erated and yielded an overall response rate (ORR) of partial response or better of 95.8% (95% confide

155 vestigator-assessed objective response rate (ORR) per the Lugano 2014 criteria and safety.

156 The objective response rate (ORR) to pembrolizumab was 56% (complete response [24%] p

157 primary end point was overall response rate (ORR) using the revised International Working Group crite

158 th de novo R/R DLBCL, overall response rate (ORR) was 29%, including 11% complete response (CR).

159 -assessed confirmed objective response rate (ORR) was 43%, and duration of response was 7.4 months.

160 aluable patients, the overall response rate (ORR) was 44% (complete response [CR], 28%); among them,

161 uable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/k

162 of pain (TWP), and objective response rate (ORR) were evaluated.

163 ree survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as related

164 ree survival (PFS), objective response rate (ORR), and safety.

165 verall survival (OS), overall response rate (ORR), duration of response (DOR), clinical-benefit rate,

166 ical outcomes were: objective response rate (ORR), immune-related adverse events (irAEs), progression

167 ints included tumor objective response rate (ORR), overall survival (OS), and change in plasma 25(OH)

168 -free survival (PFS), overall response rate (ORR), overall survival (OS), and safety.

169 were correlated with overall response rate (ORR), progression-free survival (PFS), and overall survi

170 objectives included objective response rate (ORR), progression-free survival (PFS), duration of respo

171 ree survival (PFS), objective response rate (ORR), R0 resection rate, grade 3/4 adverse events, and s

172 Purpose To evaluate objective response rate (ORR), safety, and survival after TACE by using idarubici

173 oint was RECIST 1.1 objective response rate (ORR).

174 primary outcome was objective response rate (ORR).

175 oint for phase II was overall response rate (ORR).

176 n-free survival and objective response rate (ORR).

177 imary end point was objective response rate (ORR).

178 centrally assessed objective response rate (ORR); secondary end points included progression-free sur

179 rimary endpoint was objective response rate (ORR); the null hypothesis (<= 5% ORR) would be rejected

180 firmed intracranial objective response rate (ORR-IC) was evaluated in patients with measurable intrac

181 overall cohort, the objective response rate (ORR; iRECIST(14)) was 20%.

182 acy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working

183 cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising.

184 The overall response rates (ORRs; CR/PR) at 12 months were 69.2% (43.1% and 26.2%) i

185 xhibits excellent oxygen reduction reaction (ORR) activity (with a half-wave potential of 0.89 V), ou

186 and a comparable oxygen reduction reaction (ORR) activity to that of Pt/C as well as a better stabil

187 with exceptional oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) activities are

188 catalysts for the oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) in fuel cells o

189 urability for the oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) is crucial towa

190 h kinetics of the oxygen reduction reaction (ORR) and the oxygen evolution reaction (OER)(1-4) has lo

191 and establish the oxygen reduction reaction (ORR) as the major surface reaction in ambient conditions

192 er (DET) in the dioxygen reduction reaction (ORR) at neutral pH.

193 ver, the sluggish oxygen reduction reaction (ORR) at the cathode has remained a longstanding challeng

194 yrin (Co-TPP), an oxygen reduction reaction (ORR) catalyst with highly variable product selectivity,

195 l-free (PGM-free) oxygen reduction reaction (ORR) catalysts for proton exchange membrane (PEM) fuel c

196 ing highly active oxygen reduction reaction (ORR) catalysts is crucial to boost the fuel cell economy

197 irst study of the oxygen reduction reaction (ORR) catalyzed by a cofacial porphyrin scaffold accessed

198 ical study of the oxygen reduction reaction (ORR) catalyzed by iron tetraphenylporphyrin (Fe(TPP)) in

199 catalysts for the oxygen reduction reaction (ORR) cathode in proton-exchange-membrane fuel cells rema

200 In the oxygen reduction reaction (ORR) domain, the investigation of new homogeneous cataly

201 he development of oxygen reduction reaction (ORR) electrocatalysts based on earth-abundant nonpreciou

202 eplace Pt for the oxygen reduction reaction (ORR) has been a key challenge for advancing fuel cell te

203 catalysts for the oxygen reduction reaction (ORR) has been a key challenge for advancing fuel cell te

204 ctrocatalysts for oxygen reduction reaction (ORR) in acid media.

205 catalysts for the oxygen reduction reaction (ORR) in acid, and are the most promising candidates for

206 catalysts for the oxygen reduction reaction (ORR) in acid, but how Fe, N, and C precursors transform

207 catalysts for the oxygen reduction reaction (ORR) in challenging acidic media are crucial for proton-

208 materials for the oxygen reduction reaction (ORR) in fuel cells has been the objective worldwide for

209 catalysts for the oxygen reduction reaction (ORR) in fuel cells; however, their active site structure

210 urability for the oxygen-reduction reaction (ORR) in proton-exchange membrane fuel cells (PEMFCs).

211 nhancement of the oxygen reduction reaction (ORR) in the presence of L1(0)-CoMPt NPs (M = Mn, Fe, Ni,

212 The oxygen reduction reaction (ORR) is a critical reaction in secondary batteries based

213 -electron (2e(-)) oxygen reduction reaction (ORR) is an attractive alternative to the industrial anth

214 The oxygen reduction reaction (ORR) is considered the cornerstone for regenerative ener

215 The oxygen reduction reaction (ORR) is the cathode reaction in fuel cells and its selec

216 splay outstanding oxygen reduction reaction (ORR) mass activity of 47 mA mg(cat.) (-1) represents 1.3

217 esulting from the oxygen reduction reaction (ORR) or hydrogen peroxide reduction on platinum, has bee

218 ing the catalytic oxygen reduction reaction (ORR) through the interaction between -OH groups in HAP a

219 ard four-electron oxygen reduction reaction (ORR) to H(2)O is a mainstream line of research for repla

220 catalysts for the oxygen reduction reaction (ORR) to overcome sluggish kinetics and catalyst instabil

221 SACs catalyze the oxygen reduction reaction (ORR) via a 2 e(-) pathway with a high H(2) O(2) selectiv

222 to facilitate the oxygen reduction reaction (ORR), and the key factor enabling their success is to re

223 catalysts for the oxygen reduction reaction (ORR), due to the controllable architectures, excellent e

224 in the context of oxygen reduction reaction (ORR), electrochemical CO(2) reduction reaction (CO(2) RR

225 action (HER), the oxygen reduction reaction (ORR), the CO(2) reduction reaction (CO(2) RR), the nitro

226 for the cathodic oxygen reduction reaction (ORR), which demands a comprehensive understanding of the

227 s of the cathodic oxygen reduction reaction (ORR), which requires a significant amount of Pt-based ca

228 tivity toward the oxygen reduction reaction (ORR), while the inner Ni-N(4) clusters are responsible f

229 d kinetics of the oxygen reduction reaction (ORR).

230 electrocatalytic oxygen reduction reaction (ORR).

231 high activity for oxygen reduction reaction (ORR).

232 action (OER), and oxygen reduction reaction (ORR).

233 form the sluggish oxygen reduction reaction (ORR).

234 electrocatalytic oxygen reduction reaction (ORR).

235 catalyst for the oxygen reduction reaction (ORR).

236 or catalyzing the oxygen reduction reaction (ORR).

237 ing blocks on the oxygen reduction reaction (ORR).

238 eaction, OER, and oxygen reduction reaction, ORR) and nitrogen (i.e., nitrogen reduction reaction, NR

239 th oxygen reduction and evolution reactions (ORR and OER) at high rates at thermodynamic potentials.

240 l electrocatalysts for the oxygen reduction (ORR) are highly desirable for several electrochemical de

241 hydrogen evolution (HER), oxygen reduction (ORR), and oxygen evolution (OER) reactions.

242 statistics of the ordinary ridge regression (ORR) have the same patterns across the genome as those o

243 ron porphyrins are among the most researched ORR catalysts.

244 Herein we used Oak Ridge Reservation (ORR) as a model nitrate-contaminated acidic environment

245 R activity) and Pt/C (92 % vs. 78 % retained ORR activity after 10 h running) in alkaline electrolyte

246 bringing new opportunities to revolutionize ORR catalysis in terms of cost, activity and durability.

247 The primary cohort's ORR(W15) was 41% (95% CI, 26% to 58%), including 13 part

248 Herein, a hetero-single-atom (h-SA) ORR electrocatalyst is presented, which has atomically d

249 l (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality

250 There was no statistically significant ORR difference between arms (34.5% [95% CI, 19.9% to 52.

251 Similar ORR and estimated median OS were observed in patients >=

252 chanisms which enable enhanced and sustained ORR activity and the practical methods to achieve them i

253 The ORR for the overall population was 33% and 50% in patien

254 The ORR of the mFOLFOXIRI plus panitumumab arm exceeded 75%

255 The ORR rate (~10(6) M(-1) s(-1)) and selectivity of the -N(

256 The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference

257 The ORR was 18%, including one confirmed complete response a

258 The ORR was 64%.

259 The ORR was 85.5% (94 of 110 patients; n = 1 complete respon

260 The ORR(Wk24) was 38.0% (95% CI, 28.8% to 47.8%).

261 uttering, as a fast method for assessing the ORR activity of binary alloys.

262 ent electrocatalytic activities for both the ORR and the OER in alkaline aqueous solutions.

263 e, to reduce H(2) O(2) generation during the ORR on the Co catalysts, potential strategies are outlin

264 recruited to power the study to evaluate the ORR(W15) difference between PD-L1+ and PD-L1- patients,

265 ncept of utilizing dual active sites for the ORR and demonstrate its effectiveness by synthesizing a

266 ed as the most promising composition for the ORR and employed as a target for nanoparticle synthesis.

267 reactivities of Fe-N(4) and Ni-N(4) for the ORR and OER.

268 efficient and stable electrocatalyst for the ORR and the OER in alkaline electrolytes, and shows prom

269 field are the nature of active sites for the ORR and the reaction mechanism.

270 electrocatalysts have been designed for the ORR or the OER; however, the origin of the advanced acti

271 in, the focus is on Co-N-C catalysts for the ORR relevant to PEMFC applications.

272 rin catalysts have long been studied for the ORR, but the origins of their selectivity are not well u

273 ikely candidates as the active sites for the ORR.

274 he surface provided the active sites for the ORR.

275 However, the ORR activity of current Fe-N-C is seriously limited by t

276 us panitumumab) was considered active if the ORR was >= 75%.

277 of oxygen on the Fe ion and thus improve the ORR activity.

278 WT metastatic colorectal cancer improved the ORR and rate of secondary resection of metastases and re

279 of these prisms, which in turn modulates the ORR reactivity with respect to selectivity and kinetics.

280 ccumulated a vast wealth of knowledge of the ORR on extended Pt and Pt-alloy model surfaces.

281 demands a comprehensive understanding of the ORR processes on these catalysts under reaction conditio

282 of variations in the solvation shell on the ORR.

283 echanism shows the potential to overcome the ORR energy barrier bottleneck to develop highly active c

284 s of 5 nm L1(0)-CoMPt NPs, we could push the ORR catalytic activity of these NPs toward the optimum r

285 In this subgroup, the ORR was 37% in the treatment arm versus 2% in the placeb

286 Among subgroups, the ORR(Wk24) (95% CI) was 63.6% (30.8% to 89.1%) in patient

287 omplete response [CR], 28%); among them, the ORR was 65% (CR, 41%) in non-GCB and 69% and 56% in rela

288 on, resulting in a mass activity towards the ORR of 16.37 amperes per milligram of palladium at 0.9 v

289 at disease progression and compared with the ORR by using the Wilcoxon rank sum test and with PFS by

290 coefficient [Formula: see text] and with the ORR rate constant [Formula: see text] in nonaqueous Li-,

291 The primary end point was met, with the ORR reaching 60.9% (95% CI, 45.4% to 74.9%), consisting

292 ravel the evolution pathway of precursors to ORR-active catalyst comprised exclusively of single-atom

293 but how Fe, N, and C precursors transform to ORR-active sites during pyrolysis remains unclear.

294 -dose and standard-dose vitamin D3 for tumor ORR (58% vs 63%, respectively; difference, -5% [95% CI,

295 izations and theories in order to understand ORR in the more complex Pt-alloy nanocatalysts.

296 The primary end point was ORR in nonirradiated lesions, which was assessed by RECI

297 s objective response rate (ORR) at 24 weeks (ORR(Wk24)); secondary efficacy end points included durat

298 se three time points was not associated with ORR (P = .63, .29, and .27, respectively) or PFS (P = .2

299 gh tumor viral status did not correlate with ORR, PFS, or OS, there was a trend toward improved PFS a

300 esponse [32%]; 95% CI, 41.3% to 70.0%), with ORRs of 59% in virus-positive and 53% in virus-negative

301 acarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively.